US2017232069A1PendingUtilityA1

Compositions for the treatment of peritonitis

34
Assignee: Reponex Pharmaceuticals ApsPriority: Aug 7, 2014Filed: Aug 7, 2015Published: Aug 17, 2017
Est. expiryAug 7, 2034(~8 yrs left)· nominal 20-yr term from priority
Inventors:Lars HesletLars Otto Uttenthal
A61P 43/00A61P 29/00A61P 31/04A61P 31/00A61K 31/4164A61K 9/0019A61K 31/665A61K 38/193
34
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

The present invention provides compositions comprising granulocyte-macrophage colony-stimulating factor and antimicrobial agents for the treatment, pre-emptive treatment or prevention of infectious peritonitis or intra-abdominal infection by intraperitoneal administration of the compositions.

Claims

exact text as granted — not AI-modified
1 . A kit comprising:
 (i) a first composition comprising a granulocyte-macrophage colony-stimulating factor (GM-CSF), molgramostim or sargramostim; and   (ii) a second composition comprising one or more antimicrobial or antibiotic agents, wherein said first and second compositions are formulated for intraperitoneal administration.   
     
     
         2 - 68 . (canceled) 
     
     
         69 . The kit according to  claim 1 , wherein said one or more antimicrobial or antibiotic agents comprise fosfomycin. 
     
     
         70 . The kit according to  claim 1 , wherein said one or more antimicrobial or antibiotic agents comprise fosfomycin and one or more additional antimicrobial or antibiotic agents that inhibit  Bacteroides fragilis.    
     
     
         71 . The kit according to  claim 70 , wherein said one or more antimicrobial or antibiotic agents is metronidazole. 
     
     
         72 . The kit according to  claim 70 , wherein said one or more antimicrobial or antibiotic agent that inhibits  Bacteroides fragilis  is a carbapenem or an imipenem. 
     
     
         73 . The kit according to  claim 1 , wherein the amino acid sequence of said GM-CSF is at least 70% identical to SEQ ID NO: 1 or 2. 
     
     
         74 . The kit according to  claim 1 , wherein said first composition comprises a dose of between 5 and 1000 micrograms of GM-CSF, molgramostim or sargramostim. 
     
     
         75 . The kit according to  claim 1 , wherein said second composition comprises a dose of between 500 milligram and 12 gram of fosfomycin. 
     
     
         76 . A method for the treatment or inhibition of infectious peritonitis or intra-abdominal infection in a subject, said method comprising:
 (i) administering to said subject a therapeutically effective amount of a first composition comprising a granulocyte-macrophage colony-stimulating factor (GM-CSF), molgramostim or sargramostim; and   (ii) administering to said subject a therapeutically effective amount of a second composition comprising one or more antimicrobial or antibiotic agents, wherein said first and second compositions are administered by an intraperitoneal route.   
     
     
         77 . A pharmaceutical composition comprising a granulocyte-macrophage colony-stimulating factor (GM-CSF), molgramostim or sargramostim and one or more antimicrobial or antibiotic agents. 
     
     
         78 . The pharmaceutical composition according to  claim 77 , wherein the one or more antimicrobial or antibiotic agents comprise fosfomycin. 
     
     
         79 . The pharmaceutical composition according to  claim 77 , wherein the one or more antimicrobial or antibiotic agents comprise fosfomycin and one or more additional antimicrobial or antibiotic agents that inhibit  Bacteroides fragilis.    
     
     
         80 . The pharmaceutical composition according to  claim 79 , wherein the additional antimicrobial or antibiotic agent that inhibits  Bacteroides fragilis  is metronidazole. 
     
     
         81 . The pharmaceutical composition according to  claim 79 , wherein the additional antimicrobial or antibiotic agent that inhibits  Bacteroides fragilis  is a carbapenem, or an imipenem. 
     
     
         82 . The pharmaceutical composition according to  claim 77 , wherein the antimicrobial or antibiotic agents comprise one or more antifungal agents. 
     
     
         83 . The pharmaceutical composition according to  claim 77 , wherein the GM-CSF, molgramostim or sargramostim is provided in a liposome, micelle, microcapsule or nanoparticle formulation. 
     
     
         84 . The pharmaceutical composition according to  claim 77 , wherein the amino acid sequence of the GM-CSF is at least 70% identical to SEQ ID NO: 1 or 2. 
     
     
         85 . The pharmaceutical composition according to  claim 77 , wherein the composition comprises a dose of between 5 and 1000 micrograms of GM-CSF, molgramostim or sargramostim. 
     
     
         86 . The pharmaceutical composition according to  claim 78 , wherein the composition comprises a dose of between 500 milligram and 12 gram of fosfomycin. 
     
     
         87 . The pharmaceutical composition according to  claim 77 , wherein the composition is formulated for intraperitoneal administration.

Join the waitlist — get patent alerts

Track US2017232069A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.